dpp 4 inhibitor and glp 1 agonist Specific actions of GLP-1 receptor agonists DPP4 inhibitors for the treatment of pancreatic β-cell impairments in type 2 diabetes Frontiers | Clinical Use of

Further research is warranted to explore long-term outcomes and optimize treatment protocols for this patient population

[DOI] [PubMed] [Google Scholar] 64.Astrup A., Rossner S., Van Gaal L., Rissanen A., Niskanen L., Al Hakim M

Randomized open-label trial of semaglutide and dapagliflozin in patients with type 2 diabetes of different pathophysiology

[DOI] [PubMed] [Google Scholar] 73.Vertongen P, et al

Dulaglutide (Trulicity) Trulicity earned FDA approval on September 18, 2014 and quickly became a popular weekly injection for type 2 diabetes

The company reported favorable Phase 3 results last month, saying that it is on track to submit the drug for regulatory approval by year-end